Ningxia Zhongke Biotechnology Co., Ltd

SHSE:600165 Stock Report

Market Cap: CN¥1.3b

Ningxia Zhongke Biotechnology Past Earnings Performance

Past criteria checks 0/6

Ningxia Zhongke Biotechnology's earnings have been declining at an average annual rate of -63.9%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 12.7% per year.

Key information

-63.9%

Earnings growth rate

-63.8%

EPS growth rate

Chemicals Industry Growth12.1%
Revenue growth rate12.7%
Return on equityn/a
Net Margin-240.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenues Not Telling The Story For Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) After Shares Rise 25%

Nov 13
Revenues Not Telling The Story For Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) After Shares Rise 25%

What Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 34% Share Price Gain Is Not Telling You

Aug 30
What Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 34% Share Price Gain Is Not Telling You

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump

Jul 12
Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump

Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)

Jun 03
Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless

Apr 21
Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless

Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues

Feb 27
Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues

Revenue & Expenses Breakdown

How Ningxia Zhongke Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600165 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24302-7252314
30 Jun 24297-7542015
31 Mar 24293-4595214
31 Dec 23286-4665214
30 Sep 23244-34010313
30 Jun 23308-28712615
31 Mar 23561-17710022
31 Dec 22681-14110226
30 Sep 22712-1697435
30 Jun 22642-1464834
31 Mar 22377-1924326
31 Dec 21249-1663620
30 Sep 2119513338
30 Jun 2116116303
31 Mar 2113722272
31 Dec 2011921261
30 Sep 2093-24331
30 Jun 20199-28341
31 Mar 20237-38351
31 Dec 19266-45381
30 Sep 19311-22402
30 Jun 19324-10451
31 Mar 194394461
31 Dec 185529441
30 Sep 1858639-20-3
30 Jun 181,01946321
31 Mar 181,17437721
31 Dec 171,248381101
30 Sep 171,423-1112464
30 Jun 171,756-1512370
31 Mar 172,382-1702320
31 Dec 162,785-1922250
30 Sep 162,937-181690
30 Jun 162,288511520
31 Mar 161,550581420
31 Dec 151,077461310
30 Sep 15833-1191320
30 Jun 15993-1821350
31 Mar 151,152-2001420
31 Dec 141,343-1081500
30 Sep 141,209-71620
30 Jun 141,490181690
31 Mar 141,760631650
31 Dec 131,76481580

Quality Earnings: 600165 is currently unprofitable.

Growing Profit Margin: 600165 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600165 is unprofitable, and losses have increased over the past 5 years at a rate of 63.9% per year.

Accelerating Growth: Unable to compare 600165's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 600165 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-5.3%).


Return on Equity

High ROE: 600165's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies